Article ; Online: Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy.
Journal of biomolecular structure & dynamics
2019 Volume 38, Issue 3, Page(s) 901–917
Abstract: Methotrexate is a widely used anti-metabolite in cancer chemotherapy. A series of halogenated drugs is designed from Methotrexate to assess their interactions with human dihydrofolate reductase. The aim of this study is to evaluate the performance of the ...
| Abstract | Methotrexate is a widely used anti-metabolite in cancer chemotherapy. A series of halogenated drugs is designed from Methotrexate to assess their interactions with human dihydrofolate reductase. The aim of this study is to evaluate the performance of the modified drugs compared to the parent Methotrexate. Density Functional Theory is employed to optimize these drugs. Molecular docking calculation of these optimized drugs against dihydrofolate reductase is performed to find out binding affinity. In addition, molecular dynamics simulation is considered for the complexes of best two modified drugs with their receptors. Modifications by the halogens show significant changes in the charge distribution, dipole moment, thermodynamic stability, enthalpy and free energy. The highest binding affinity value (-36.401 KJ/mol) was obtained for M14. Hybrid quantum mechanics/molecular mechanics calculation shows a binding energy of -255.140 KJ/mol. Modified drugs have significant hydrogen and non-covalent bonding interactions with amino acids of the receptor. Molecular dynamics simulation disclosed that the root-mean-square-deviation of the alpha carbon associated with M6-1KMV and M14-1KMV complexes is 2.367 Å and 2.622 Å, respectively. Moreover, the interactions between modified drugs and receptor are mostly persevered in 25 nanosecond molecular dynamics simulation. Ensemble-based docking also confirmed that modified drugs show strong non-bonding interactions with different crystallographic and molecular dynamics based conformers. The best scored drugs show considerable pharmacokinetic properties. Modified derivatives M5, M6, M8, M10, M13 and M14 show the better binding affinity and a good number of hydrogen and other non-bonding interactions with the target protein which are similar to other anticancer drugs.Communicated by Ramaswamy H. Sarma. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Folic Acid Antagonists/pharmacokinetics ; Folic Acid Antagonists/pharmacology ; Folic Acid Antagonists/therapeutic use ; Halogens/chemistry ; Humans ; Hydrogen Bonding ; Methotrexate/chemistry ; Methotrexate/pharmacokinetics ; Methotrexate/pharmacology ; Methotrexate/therapeutic use ; Molecular Docking Simulation ; Neoplasms/drug therapy ; Protein Binding ; Tetrahydrofolate Dehydrogenase/metabolism ; Thermodynamics | |||||
| Chemical Substances | Folic Acid Antagonists ; Halogens ; Tetrahydrofolate Dehydrogenase (EC 1.5.1.3) ; Methotrexate (YL5FZ2Y5U1) | |||||
| Language | English | |||||
| Publishing date | 2019-04-02 | |||||
| Publishing country | England | |||||
| Document type | Journal Article ; Research Support, Non-U.S. Gov't | |||||
| ZDB-ID | 49157-3 | |||||
| ISSN | 1538-0254 ; 0739-1102 | |||||
| ISSN (online) | 1538-0254 | |||||
| ISSN | 0739-1102 | |||||
| DOI | 10.1080/07391102.2019.1591302 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2093: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.